Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 142

1.

Impact of advanced age on myocardial perfusion, distal embolization, and mortality patients with ST-segment elevation myocardial infarction treated by primary angioplasty and glycoprotein IIb-IIIa inhibitors.

De Luca G, van't Hof AW, Huber K, Gibson CM, Bellandi F, Arntz HR, Maioli M, Noc M, Zorman S, Secco GG, Zeymer U, Gabriel HM, Emre A, Cutlip D, Rakowski T, Gyongyosi M, Dudek D.

Heart Vessels. 2014 Jan;29(1):15-20. doi: 10.1007/s00380-013-0323-4. Epub 2013 Mar 14.

PMID:
23494604
2.

Diabetes mellitus is associated with distal embolization, impaired myocardial perfusion, and higher mortality in patients with ST-segment elevation myocardial infarction treated with primary angioplasty and glycoprotein IIb-IIIa inhibitors.

De Luca G, Gibson CM, Bellandi F, Noc M, Dudek D, Zeymer U, Arntz HR, Cutlip D, Maioli M, Zorman S, Mesquita Gabriel H, Emre A, Rakowski T, Gyongyosi M, Huber K, Van't Hof AW.

Atherosclerosis. 2009 Nov;207(1):181-5. doi: 10.1016/j.atherosclerosis.2009.03.042. Epub 2009 Apr 5.

PMID:
19426981
3.

Impact of preprocedural TIMI flow on myocardial perfusion, distal embolization and mortality in patients with ST-segment elevation myocardial infarction treated by primary angioplasty and glycoprotein IIb/IIIa inhibitors.

Maioli M, Zeymer U, van 't Hof AW, Gibson CM, Dudek D, Bellandi F, Noc M, Secco GG, Zorman S, Gabriel HM, Emre A, Cutlip D, Rakowski T, Gyongyosi M, Huber K, De Luca G; EGYPT Cooperation.

J Invasive Cardiol. 2012 Jul;24(7):324-7.

4.

Impact of time-to-treatment on myocardial perfusion after primary percutaneous coronary intervention with Gp IIb-IIIa inhibitors.

De Luca G, Gibson MC, Hof AW, Cutlip D, Zeymer U, Noc M, Maioli M, Zorman S, Gabriel MH, Secco GG, Emre A, Dudek D, Rakowski T, Gyongyosi M, Huber K, Bellandi F; EGYPT cooperation.

J Cardiovasc Med (Hagerstown). 2013 Nov;14(11):815-20. doi: 10.2459/JCM.0b013e32835fcb38.

PMID:
23519096
5.

Impact of distal embolization on myocardial perfusion and survival among patients undergoing primary angioplasty with glycoprotein IIb-IIIa inhibitors: insights from the EGYPT cooperation.

De Luca G, Gibson CM, Bellandi F, Noc M, Maioli M, Zorman S, Zeymer U, Gabriel HM, Emre A, Cutlip D, Arntz HR, Dudek D, Rakowski T, Gyongyosi M, Huber K, van't Hof AW.

J Thromb Thrombolysis. 2010 Jul;30(1):23-8. doi: 10.1007/s11239-009-0419-y.

PMID:
19921103
6.

Gender-related differences in outcome after ST-segment elevation myocardial infarction treated by primary angioplasty and glycoprotein IIb-IIIa inhibitors: insights from the EGYPT cooperation.

De Luca G, Gibson CM, Gyöngyösi M, Zeymer U, Dudek D, Arntz HR, Bellandi F, Maioli M, Noc M, Zorman S, Gabriel HM, Emre A, Cutlip D, Rakowski T, Huber K, van't Hof AW.

J Thromb Thrombolysis. 2010 Oct;30(3):342-6. doi: 10.1007/s11239-010-0451-y.

PMID:
20213259
7.

Association between advanced Killip class at presentation and impaired myocardial perfusion among patients with ST-segment elevation myocardial infarction treated with primary angioplasty and adjunctive glycoprotein IIb-IIIa inhibitors.

De Luca G, Gibson CM, Huber K, Zeymer U, Dudek D, Cutlip D, Bellandi F, Noc M, Emre A, Zorman S, Gabriel HM, Maioli M, Rakowski T, Gyöngyösi M, Van't Hof AW; EGYPT Cooperation.

Am Heart J. 2009 Sep;158(3):416-21. doi: 10.1016/j.ahj.2009.06.029.

PMID:
19699865
8.

Impact of multivessel disease on myocardial perfusion and survival among patients undergoing primary percutaneous coronary intervention with glycoprotein IIb/IIIa inhibitors.

De Luca G, Gibson M, Cutlip D, Huber K, Dudek D, Bellandi F, Noc M, Maioli M, Zorman S, Zeymer U, Secco GG, Mesquita Gabriel H, Emre A, Arntz HR, Rakowski T, Gyongyosi M, Hof AW; EGYPT Cooperation.

Arch Cardiovasc Dis. 2013 Mar;106(3):155-61. doi: 10.1016/j.acvd.2012.12.007. Epub 2013 Apr 2.

9.

Time-related impact of distal embolisation on myocardial perfusion and survival among patients undergoing primary angioplasty with glycoprotein IIb-IIIa inhibitors: insights from the EGYPT cooperation.

De Luca G, Gibson CM, Huber K, Dudek D, Cutlip D, Zeymer U, Gyöngyösi M, Bellandi F, Noc M, Arntz HR, Maioli M, Secco GG, Zorman S, Gabriel HM, Emre A, Rakowski T, Van't Hof AW; EGYPT cooperation.

EuroIntervention. 2012 Aug;8(4):470-6. doi: 10.4244/EIJV8I4A74.

10.

Early glycoprotein IIb-IIIa inhibitors in primary angioplasty (EGYPT) cooperation: an individual patient data meta-analysis.

De Luca G, Gibson CM, Bellandi F, Murphy S, Maioli M, Noc M, Zeymer U, Dudek D, Arntz HR, Zorman S, Gabriel HM, Emre A, Cutlip D, Biondi-Zoccai G, Rakowski T, Gyongyosi M, Marino P, Huber K, van't Hof AW.

Heart. 2008 Dec;94(12):1548-58. doi: 10.1136/hrt.2008.141648. Epub 2008 May 12. Review.

11.

Impact of time from symptom onset to drug administration on outcome in patients undergoing glycoprotein IIb-IIIa facilitated primary angioplasty (from the EGYPT cooperation).

De Luca G, Van't Hof AW, Gibson CM, Cutlip D, Zeymer U, Noc M, Maioli M, Zorman S, Gabriel HM, Emre A, Rakowski T, Gyongyosi M, Huber K, Bellandi F, Dudek D; EGYPT cooperation.

Am J Cardiol. 2015 Mar 15;115(6):711-5. doi: 10.1016/j.amjcard.2014.12.030. Epub 2015 Jan 6.

PMID:
25655867
12.

Impact of hypertension on distal embolization, myocardial perfusion, and mortality in patients with ST segment elevation myocardial infarction undergoing primary angioplasty.

De Luca G, van't Hof AW, Huber K, Gibson CM, Bellandi F, Arntz HR, Maioli M, Noc M, Zorman S, Zeymer U, Gabriel HM, Emre A, Cutlip D, Rakowski T, Gyongyosi M, Dudek D; EGYPT cooperation.

Am J Cardiol. 2013 Oct 15;112(8):1083-6. doi: 10.1016/j.amjcard.2013.05.053. Epub 2013 Aug 1.

PMID:
23910428
14.

Facilitated angioplasty with combo therapy among patients with ST-segment elevation myocardial infarction: a meta-analysis of randomized trials.

De Luca G, Marino P.

Am J Emerg Med. 2009 Jul;27(6):683-90. doi: 10.1016/j.ajem.2008.05.021.

PMID:
19751625
15.

Platelet GP IIb-IIIa Receptor Antagonists in Primary Angioplasty: Back to the Future.

De Luca G, Savonitto S, van't Hof AW, Suryapranata H.

Drugs. 2015 Jul;75(11):1229-53. doi: 10.1007/s40265-015-0425-7. Review.

PMID:
26177890
16.
17.

Clinical outcome of patients with diabetes presenting with ST-elevation myocardial infarction and treated with concomitant use of glycoprotein IIb/IIIa inhibitors.

Kralev S, Krause B, Papavassiliu T, Lang S, Haghi D, Kälsch T, Dempfle CE, Borggrefe M, Süselbeck T.

Cardiol J. 2009;16(3):234-40.

18.
19.

Impact of diabetes on long-term outcome in STEMI patients undergoing primary angioplasty with glycoprotein IIb-IIIa inhibitors and BMS or DES.

De Luca G, Sauro R, Varricchio A, Capasso M, Lanzillo T, Manganelli F, Mariello C, Siano F, Carbone G, Pagliuca MR, Rosato G, Di Lorenzo E.

J Thromb Thrombolysis. 2010 Aug;30(2):133-41. doi: 10.1007/s11239-009-0420-5.

PMID:
19921102
20.

Benefits of pharmacological facilitation with glycoprotein IIb-IIIa inhibitors in diabetic patients undergoing primary angioplasty for STEMI. A subanalysis of the EGYPT cooperation.

De Luca G, Michael Gibson C, Bellandi F, Murphy S, Maioli M, Noc M, Zeymer U, Dudek D, Arntz HR, Zorman S, Gabriel HM, Emre A, Cutlip D, Rakowski T, Gyongyosi M, Huber K, Van't Hof AW.

J Thromb Thrombolysis. 2009 Oct;28(3):288-98. doi: 10.1007/s11239-008-0296-9. Epub 2008 Nov 22.

PMID:
19030969

Supplemental Content

Support Center